Prevalence of Dysplasia in Juvenile-Onset Recurrent Respiratory Papillomatosis

Sajan, Javad A.; Kerschner, Joseph E.; Meratı, Albert L.; Osipov, Vladimir; Szabo, Sara; Blumin, Joel H.

doi:10.1001/archoto.2009.179

Cited by 23 publications

(20 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In juvenile-onset RRP group eight cases showed signs of only histologically evident keratosis, including one case of slight epithelium dysplasia (16 years old girl). These findings correspond with the data of literature that dysplasia is a rare event in pediatric RRP [33].…”

Section: Patientssupporting

confidence: 92%

Expression of matrix metalloproteinases (MMP-2 and MMP-9) in recurrent respiratory papillomas and laryngeal carcinoma: clinical and morphological parallels

Uloza¹,

Liutkevičius²,

Pangonytė

et al. 2011

Eur Arch Otorhinolaryngol

View full text Add to dashboard Cite

The task of the present study was to investigate the expression of MMP-2 and MMP-9 in recurrent respiratory papillomas (RRP) and accomplish a comparative analysis with those in laryngeal squamous cell carcinoma (LSCC). The immunohistochemical expression of MMP-2 and MMP-9 was investigated in specimens taken from RRP (n = 38) and LSCC (n = 39) patient groups, and the normal tissue of vocal fold (n = 12, control group). The expression of MMP-2 and MMP-9, both in epithelium and stroma cells, was graded on a semiquantitative scale, ranging from 0 (no expression) to 18 points (high expression). Statistically significant differences in the expression of MMP-2 and MMP-9, both in epithelium and stroma among the RRP, LSCC patients and control group (epithelium) with the LSCC group having the highest MMPs expression scores were revealed. However, no statistically significant correlations among expression of MMPs and clinical and/or morphological features were found in the group of RRP patients. The MMP-2 stroma value of 10.4 points was determined as the optimum point (limiting value) for separating RRP and LSCC patient groups. Results of the present study indicate that the expression of both MMP-2 and MMP-9 are up-regulated early in development of laryngeal papillomas, when the benign neoplastic lesion begins and the next determinant step is concerned with the occurrence of malignization. These results seem promising, as they may improve our understanding of the molecular events leading to the papilloma formation and development, however, further research is needed.

show abstract

Section: Patientssupporting

confidence: 92%

Expression of matrix metalloproteinases (MMP-2 and MMP-9) in recurrent respiratory papillomas and laryngeal carcinoma: clinical and morphological parallels

Uloza¹,

Liutkevičius²,

Pangonytė

et al. 2011

Eur Arch Otorhinolaryngol

View full text Add to dashboard Cite

show abstract

“…In this setting it is typically administered as an intravenous infusion, where it is known to cause nephrotoxicity, hepatic dysfunction, hematopoietic dysfunction, and ocular toxicity 8. Although case reports have raised concern for carcinogenicity,9 histologic studies of human specimens have shown no evidence to support this relationship 10–12. Prior surveys and case series have estimated that 2% to 3% of patients with RRP develop squamous cell carcinoma of the upper aerodigestive tract2; however, this appears to be equivalent in patients with and without exposure to cidofovir 11, 12.…”

Section: Introductionmentioning

confidence: 99%

Current use of intralesional cidofovir for recurrent respiratory papillomatosis

et al. 2012

View full text Add to dashboard Cite

Eighteen statements were approved by the RRP Task Force after discussion of the survey results. Intralesional cidofovir may be initiated if surgical debulking is required every 2 to 3 months. The concept of an adjuvant regimen with regular biopsy is favored. Administration should remain below established safe limits of dosing (3 mg/kg) and volume. Informed consent, including discussion of off-label use and acute kidney injury in children, is important. A special consent form sample is included. There remains a need for high-quality data.

show abstract

“…Its treatment efficacy can be as high as 80% (according to RRPF; see Table I). Due to the risk of nephro-and hepatotoxicity (according to Sajan et al [8]), the treatment is recommended for patients with a history of severe and resistant disease. The efficacy of cidofovir and its side effects have been discussed in Europe for some time.…”

Section: Discussionmentioning

confidence: 99%

Uncontrolled human papilloma virus infection in a 28-year-old man leading to death – and review of literature

Szybiak¹,

Marszałek²,

Łuczewski³

et al. 2015

pjp

View full text Add to dashboard Cite

Prevalence of Dysplasia in Juvenile-Onset Recurrent Respiratory Papillomatosis

Abstract: Dysplasia is a rare event in pediatric recurrent respiratory papillomatosis, and there does not appear to be an association between the use of cidofovir and dysplastic changes.

Cited by 23 publications

References 14 publications

Expression of matrix metalloproteinases (MMP-2 and MMP-9) in recurrent respiratory papillomas and laryngeal carcinoma: clinical and morphological parallels

Expression of matrix metalloproteinases (MMP-2 and MMP-9) in recurrent respiratory papillomas and laryngeal carcinoma: clinical and morphological parallels

Current use of intralesional cidofovir for recurrent respiratory papillomatosis

Uncontrolled human papilloma virus infection in a 28-year-old man leading to death – and review of literature

Contact Info

Product

Resources

About